Literature DB >> 15375530

Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.

M Murai1, X Shen, L Huang, W M Carpenter, C S Lin, S Silverman, J Regezi, R H Kramer.   

Abstract

Hepatocyte growth factor (HGF), the ligand for the c-met proto-oncogene product, is a multifunctional protein that enhances tumor cell motility, extracellular matrix invasion, and mitogenic or morphogenic activities of various cell types. In this study we examined the expression of the c-Met receptor in human oral squamous cell carcinoma (SCC) in vivo and in vitro to explore its relationship to tumor progression and invasiveness. Biopsy specimens of human oral SCC were immunohistochemically stained for c-Met. Nearly all primary oral SCC lesions and lymph node metastases consistently showed intense staining for c-Met, whereas normal oral mucosa showed faint to negative staining only on basal cells. In a panel of human oral SCC cell lines, we found a strong correlation between the levels of c-Met expression and the cells' response to HGF in motility and invasion assays. Sensitivity to HGF also correlated with the expression of the c-Met 9-kb mRNA. When the non-invasive HOC-605 cell line, which expresses a low level of c-Met receptor, was transfected with an expression plasmid containing human c-met cDNA, the transfectant cells showed motile and invasive responses to HGF. Immunostaining and immunoprecipitation studies demonstrated that E-cadherin and c-Met were physically associated at SCC cell-cell junctions, suggesting a direct role for c-Met in induction of junctional integrity. Importantly, HGF caused a rapid elevation of unbound beta-catenin, suggesting its availability for nuclear signal transduction and triggering of cell motility and invasiveness. Thus, overexpression of c-Met may facilitate disruption of E-cadherin junctions. Collectively, these results suggest that HGF/c-Met signaling is a common event in oral SCC that may trigger phenotype modulation and enhanced invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375530

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Gene expression profile changes correlated with lymph node metastasis in oral squamous cell carcinoma.

Authors:  Haruhiko Kashiwazaki; Nur Mohammad Monsur Hassan; Jun-Ichi Hamada; Tetsuya Moriuchi; Yutaka Yamazaki; Kanchu Tei; Yasunori Totsuka; Nobuo Inoue
Journal:  Odontology       Date:  2008-07-27       Impact factor: 2.634

2.  Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Authors:  Xiqiang Liu; Antonia Kolokythas; Jianguang Wang; Hongzhang Huang; Xiaofeng Zhou
Journal:  Curr Cancer Ther Rev       Date:  2010-11-01

3.  Changes in expression of oncogenes and TP53 tumour suppressor gene as biomarkers in head and neck cancers.

Authors:  István Szanyi; Miklós Bauer; Imre Gerlinger; Tamás Járai; Gyula Gobel; László Lujber; Eva Szabadi; Katalin Fehér; Agoston Émber; István Ember; István Kiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-12-01       Impact factor: 2.503

4.  Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.

Authors:  Yiru Xu; Jin Zhou; Thomas E Carey; Jonathan B McHugh; John J Voorhees; Gary J Fisher
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

5.  A miR-34a-SIRT6 axis in the squamous cell differentiation network.

Authors:  Karine Lefort; Yang Brooks; Paola Ostano; Muriel Cario-André; Valérie Calpini; Juan Guinea-Viniegra; Andrea Albinger-Hegyi; Wolfram Hoetzenecker; Ingrid Kolfschoten; Erwin F Wagner; Sabine Werner; Gian Paolo Dotto
Journal:  EMBO J       Date:  2013-07-16       Impact factor: 11.598

6.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

7.  Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.

Authors:  N M Ayoub; M R Akl; P W Sylvester
Journal:  Cell Prolif       Date:  2013-08-23       Impact factor: 6.831

8.  Prognostic value of c-Met expression in oral squamous cell carcinoma.

Authors:  Christian Freudlsperger; Dorothea Alexander; Siegmar Reinert; Juergen Hoffmann
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

9.  Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.

Authors:  Lisa Mohamet; Kate Hawkins; Christopher M Ward
Journal:  J Oncol       Date:  2010-12-09       Impact factor: 4.375

10.  Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.

Authors:  J B Tuynman; S M Lagarde; F J W Ten Kate; D J Richel; J J B van Lanschot
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.